CX Institutional Has $682,000 Stake in Danaher Co. (NYSE:DHR)

CX Institutional boosted its holdings in Danaher Co. (NYSE:DHR) by 2.1% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,970 shares of the conglomerate’s stock after purchasing an additional 62 shares during the quarter. CX Institutional’s holdings in Danaher were worth $682,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. FMR LLC raised its stake in Danaher by 15.8% in the 3rd quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after buying an additional 148,251 shares during the period. Fisher Asset Management LLC increased its holdings in Danaher by 2.6% in the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after buying an additional 116,299 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in Danaher by 17.6% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock valued at $996,141,000 after buying an additional 535,254 shares during the period. Finally, Montrusco Bolton Investments Inc. increased its holdings in Danaher by 30.4% in the 3rd quarter. Montrusco Bolton Investments Inc. now owns 1,705,884 shares of the conglomerate’s stock valued at $465,617,000 after buying an additional 397,671 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of several recent analyst reports. Royal Bank of Canada decreased their target price on shares of Danaher from $333.00 to $311.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. KeyCorp raised their target price on shares of Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a report on Wednesday, October 23rd. Robert W. Baird decreased their target price on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Evercore ISI lifted their price target on shares of Danaher from $275.00 to $278.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Finally, Scotiabank assumed coverage on shares of Danaher in a report on Monday, December 23rd. They set a “sector perform” rating and a $265.00 price target on the stock. Six research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Danaher has a consensus rating of “Moderate Buy” and a consensus price target of $285.55.

Danaher Stock Up 0.1 %

Shares of NYSE DHR opened at $245.95 on Friday. The company has a market capitalization of $177.65 billion, a P/E ratio of 46.94, a price-to-earnings-growth ratio of 4.43 and a beta of 0.83. Danaher Co. has a 52-week low of $225.42 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The company’s 50 day moving average price is $235.33 and its 200-day moving average price is $253.45.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Friday, December 27th will be given a $0.27 dividend. The ex-dividend date is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.44%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.